



(12) Translation of
European patent specification

(11) NO/EP 3129018 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/33 (2006.01)
A61P 1/16 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2020.02.24
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.10.23
(86)	European Application Nr.	15728222.9
(86)	European Filing Date	2015.04.10
(87)	The European Application's Publication Date	2017.02.15
(30)	Priority	2014.04.11, US, 201461978335 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	CymaBay Therapeutics, Inc., 7575 Gateway Boulevard, Suite 110, Newark, CA 94560, USA
(72)	Inventor	ROBERTS, Brian, 7575 Gateway Boulevard, Suite 110, Newark, CA 94560, USA WANG, Xueyan, 7575 Gateway Boulevard, Suite 110, Newark, CA 94560, USA CHOI, Yun-Jung, 7575 Gateway Boulevard, Suite 110, Newark, CA 94560, USA KARPF, David, 7575 Gateway Boulevard, Suite 110, Newark, CA 94560, USA MARTIN, Robert, 7575 Gateway Boulevard, Suite 110, Newark, CA 94560, USA MCWHERTER, Charles A., 7575 Gateway Boulevard, Suite 110, Newark, CA 94560, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 2003 Vika, 0125 OSLO, Norge

(54) Title **TREATMENT OF NAFLD AND NASH**

(56) References
Cited: WO-A2-2007/033231
HACZEYNI ET AL: "The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice.", HEPATOLOGY COMMUNICATIONS., vol. 1, no. 7, 2017, - 2017, pages 663-674,
SAHEBKAR AMIRHOSSEIN ET AL: "New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease", EXPERT OPINION ON PHARMACOTHERAPY, ASHLEY PUBLICATIONS LTD, LONDON, UK, vol. 15, no. 4, 1 March 2014 (2014-03-01), pages 493-503, XP009182172, ISSN: 1465-6566 [retrieved on 2014-01-16]
BAYS HAROLD E ET AL: "MBX-8025, A Novel Peroxisome Proliferator Receptor-delta Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without

Atorvastatin", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, THE ENDOCRINE SOCIETY, US, vol. 96, no. 9, 13 June 2012 (2012-06-13), pages 2889-2897, XP002677652, ISSN: 0021-972X

CHOI ET AL: "Seladelpar improves hepatic steatohepatitis and fibrosis in a diet induced and biosy confirmed mouse model of NASH", LIVER MEETING, AASLD, SAN FRANCISCO 2018, 2018, - 2018, page 1311,

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

- 5 **1.** Forbindelse som er (*R*)-2-(4-((2-etoksy-3-(4-(trifluormetyl)fenoksy)propyl)tio)-2-metylphenoksy)eddiksyre (MBX-8025) eller et salt derav for anvendelse i behandling av en tilstand som er ikke-alkoholisk fettlever sykdom eller ikke-alkoholisk steatohepatitt.
- 10 **2.** Forbindelsen for anvendelse ifølge krav 1, der forbindelsen er (*R*)-2-(4-((2-etoksy-3-(4-(trifluormetyl)fenoksy)propyl)tio)-2-metylphenoksy)eddiksyre-L-lysin-dihydratsalt.
- 3.** Forbindelsen for anvendelse ifølge krav 1 eller 2 for oral administrering.
- 15 **4.** Forbindelsen for anvendelse ifølge et hvilket som helst av kravene 1 til 3, der den daglige dosen av forbindelsen (når beregnet som den frie syren) er 20-200 mg.
- 20 **5.** Forbindelsen for anvendelse ifølge krav 4, der den daglige dosen av forbindelsen (når beregnet som den frie syren) er 50-200 mg.
- 6.** Forbindelsen for anvendelse ifølge et hvilket som helst av de foregående kravene, der forbindelsen administreres én gang/dag.
- 25 **7.** Forbindelsen for anvendelse ifølge et hvilket som helst av de foregående kravene, der tilstanden er ikke-alkoholisk fettlever sykdom.
- 8.** Forbindelsen for anvendelse ifølge et hvilket som helst av de foregående kravene, der tilstanden er ikke-alkoholisk steatohepatitt.